Metoclopramide Baxter

Metoclopramide, the active ingredient in Metoclopramide Baxter, is a dopamine antagonist presented as an injectable solution for intramuscular and intravenous administration. It is used to control nausea and vomiting, including postoperative, chemotherapy‑induced, and gastroparesis, primarily in adult patients.

GNH USA supplies Metoclopramide Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality, traceability and compliance with Good Distribution Practice throughout the supply chain and timely delivery to end‑users.

Metoclopramide is an antiemetic and gastro‑prokinetic that acts on dopamine pathways to relieve nausea and improve gastric motility. - Nausea and vomiting: reduces frequency and severity of acute nausea and vomiting. - Post‑operative nausea and vomiting: prevents and treats nausea after surgery. - Chemotherapy‑induced nausea and vomiting: mitigates nausea associated with cytotoxic therapy. - Gastroparesis: enhances gastric emptying and alleviates symptoms of delayed gastric emptying.

Metoclopramide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Restlessness: feelings of agitation or inner tension. - Diarrhea: increased bowel movements. - Extrapyramidal symptoms: muscle stiffness or tremor. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Tardive dyskinesia: persistent involuntary movements, especially with prolonged use. - Neuroleptic malignant syndrome: rare life‑threatening reaction with fever and rigidity. - Severe allergic reaction: anaphylaxis, rash, or angioedema. - Cardiac arrhythmia: abnormal heart rhythm. - Depression or suicidal thoughts: mood changes.

When prescribing Metoclopramide, clinicians should consider several precautionary measures to minimize risk. - Assess renal function: dose adjustment may be needed in renal impairment. - Limit duration: avoid use beyond 12 days to reduce risk of tardive dyskinesia. - Review CNS disorders: caution in patients with Parkinson’s disease or seizure disorders. - Monitor for depression: observe for mood changes or suicidal ideation. - Avoid in infants: not recommended for pediatric use under 1 month. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metoclopramide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Antipsychotics: may antagonize metoclopramide’s anti‑emetic effect. - MAO inhibitors: increase risk of hypertensive crisis. - CYP2D6 substrates: metoclopramide can inhibit metabolism leading to increased levels.

Moderate Interactions (Monitor Closely): - Opioids: additive CNS depression and constipation. - Anticholinergics: may reduce pro‑kinetic benefit. - SSRIs: potential for serotonin syndrome when combined with other serotonergic agents.